TD Cowen Issues Pessimistic Forecast for Bruker (NASDAQ:BRKR) Stock Price

Bruker (NASDAQ:BRKR) had its price objective cut by TD Cowen from $72.00 to $70.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “hold” rating on the medical research company’s stock. TD Cowen’s price objective would indicate a potential upside of 15.72% from the company’s previous close.

Several other brokerages have also recently weighed in on BRKR. The Goldman Sachs Group lowered their target price on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. Citigroup lowered their price objective on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. Barclays cut their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday. Wells Fargo & Company decreased their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Stock Up 2.6 %

BRKR stock opened at $60.49 on Wednesday. The firm’s 50-day moving average is $63.83 and its two-hundred day moving average is $66.47. The company has a market capitalization of $9.16 billion, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 2.32 and a beta of 1.20. Bruker has a 52 week low of $54.55 and a 52 week high of $94.86. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. Bruker’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.74 EPS. On average, analysts forecast that Bruker will post 2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BRKR. Covestor Ltd increased its stake in Bruker by 139.1% in the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after buying an additional 210 shares during the period. First Horizon Advisors Inc. increased its position in Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after purchasing an additional 218 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker during the 2nd quarter worth about $52,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Bruker by 40.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock valued at $81,000 after buying an additional 248 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.